Methyl-((R)-1-methyl-piperidin-3-yl)-amine | 1354007-31-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: Methyl-((R)-1-methyl-piperidin-3-yl)-amine
• 英文别名: (3R)-N,1-dimethylpiperidin-3-amine
• CAS: 1354007-31-0
• 化学式: C₇H₁₆N₂
• 分子量: 128.22
• InChiKey: KGECUXOREWNBGK-SSDOTTSWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY
  申请人：Li Hui

  公开号：US20100190770A1

  公开（公告）日：2010-07-29

  Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful.

  公开了化合物I的结构，含有这些化合物的组合物，以及在治疗需要调节JAK途径或抑制JAK激酶，特别是JAK 2和JAK3的情况下使用这些化合物和组合物的方法。
• NITROGEN-CONTAINING FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF
  申请人：Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

  公开号：EP3929185A1

  公开（公告）日：2021-12-29

  The present invention relates to a nitrogen-containing fused ring compound, a preparation method and use thereof. Specifically, the present invention relates to a compound having the structure of Formula (X), a stereoisomer, tautomer or mixture thereof, a pharmaceutically acceptable salt, co-crystal, polymorph or solvate thereof, or a stable isotope derivative, metabolite or prodrug thereof. The compound of the invention may have the structure of Formula (I) or Formula (II). These compounds are useful for the treatment of an abnormal cell proliferation disease (e.g., cancer).         R-L-R3     (X)

  本发明涉及一种含氮融合环化合物，其制备方法和用途。具体而言，本发明涉及具有化学式（X）结构的化合物，其立体异构体、互变异构体或它们的混合物，药学上可接受的盐、共晶体、多型体或溶剂合物，或其稳定同位素衍生物、代谢物或前药。本发明的化合物可能具有化学式（I）或化学式（II）的结构。这些化合物对于治疗异常细胞增殖疾病（例如癌症）是有用的。 R-L-R3（X）
• PYRROLOPYRIDINES AS KINASE INHIBITORS
  申请人：Array BioPharma Inc.

  公开号：US20140243520A1

  公开（公告）日：2014-08-28

  Compounds of Formula I are useful for inhibition of CHK1 and/or CHK2. Methods of using compounds of Formula I and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

  公式I的化合物对于抑制CHK1和/或CHK2非常有用。本文揭示了使用公式I的化合物、立体异构体和药学上可接受的盐，用于体外、体内和体内诊断、预防或治疗哺乳动物细胞中的这种疾病或相关病理条件的方法。
• HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF
  申请人：QIU Hui

  公开号：US20160264548A1

  公开（公告）日：2016-09-15

  The present invention relates to pyridine, pyrimidine, pyrazine, and pyridazine compounds, and pharmaceutically acceptable compositions thereof, useful as BTK inhibitors.

  本发明涉及吡啶、嘧啶、吡嗪和吡啶二嗪化合物及其药学上可接受的组合物，用作BTK抑制剂。
• N-SUBSTITUTED-N'-SUBSTITUTED UREA DERIVATIVE AND USE THEREOF AS TNF-$g(a) PRODUCTION INHIBITOR
  申请人：SANTEN PHARMACEUTICAL CO., LTD.

  公开号：EP1172359A1

  公开（公告）日：2002-01-16

  N-Substituted-N'-substituted urea derivatives represented by the following formula, analogs thereof or pharmaceutically acceptable salts thereof are herein provided. These compounds show a TNF- α production inhibitory activity.

  本文提供了由下式代表的 N-取代-N'-取代脲衍生物、其类似物或其药学上可接受的盐。这些化合物具有抑制 TNF- α 生成的活性。